Abhinav Vasudevan
Overview
Explore the profile of Abhinav Vasudevan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen A, Li Wai Suen C, Srinivasan A, Segal J, Vasudevan A
Lancet Gastroenterol Hepatol
. 2025 Feb;
10(3):193-194.
PMID: 39954688
No abstract available.
2.
Gilmore R, Fernandes R, Hartley I, Arzivian A, Leong R, Andrew B, et al.
Intest Res
. 2024 Dec;
PMID: 39709985
Background/aims: Upadacitinib is a novel selective Janus kinase inhibitor approved for use in ulcerative colitis. Clinical trials had rigorous criteria and excluded many patient subgroups. Given limited real-world effectiveness data,...
3.
Chen L, Srinivasan A, Vasudevan A
World J Gastroenterol
. 2024 Oct;
30(34):3868-3874.
PMID: 39350785
This editorial builds on the article by Shakhshir . We conducted an overview of evidence-based dietary interventions in adults with inflammatory bowel disease (IBD). In the IBD population, there may...
4.
Srinivasan A, Van Langenberg D, De Cruz P, Segal J, Vasudevan A, Upton R
BioDrugs
. 2024 Aug;
38(5):691-702.
PMID: 39168947
Background: The optimal infliximab dose intensification strategy to address loss of response associated with subtherapeutic infliximab trough levels remains uncertain, as does whether post-intensification trough and treatment targets should influence...
5.
Vootukuru N, Vasudevan A
World J Gastroenterol
. 2024 Jul;
30(22):2902-2919.
PMID: 38947290
Background: Remarkable progress over the last decade has equipped clinicians with many options in the treatment of inflammatory bowel disease. Clinicians now have the unique opportunity to provide individualized treatment...
6.
Dutt K, Vasudevan A
Aliment Pharmacol Ther
. 2024 May;
60(2):288-289.
PMID: 38779950
No abstract available.
7.
Bohra A, Batt N, Dutt K, Sluka P, Niewiadomski O, Vasudevan A, et al.
Inflamm Bowel Dis
. 2024 Mar;
31(2):476-484.
PMID: 38537201
Background: Serum free thiols (SFTs) reflecting oxidative stress appear to correlate with inflammatory bowel disease (IBD) activity. We aimed to evaluate the performance of SFTs concentrations vs endoscopic and histological...
8.
Vasudevan A, Con D, van Langenberg D
Aliment Pharmacol Ther
. 2024 Mar;
59(8):1011.
PMID: 38523135
No abstract available.
9.
Bohra A, Batt N, Dutt K, Lewis D, Segal J, Newiadomski O, et al.
Therap Adv Gastroenterol
. 2024 Mar;
17:17562848241237895.
PMID: 38486818
Background: Faecal biomarkers are increasingly utilized for disease assessment in inflammatory bowel disease (IBD). Objectives: To characterize the relative and combined accuracy of faecal calprotectin (FC) and faecal immunochemical testing...
10.
Vasudevan A, Con D, van Langenberg D
Aliment Pharmacol Ther
. 2024 Feb;
59(6):794.
PMID: 38401137
No abstract available.